R&D Drug Pipeline Database: 2-Months Subscription
Subscription to La Merie’s proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mechanism of Action, Product Category, Therapeutic Area, indication and R&D Phase. Use of the R&D database of marketed and investigational drugs is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Therapeutic Areas, Territories, Product Categories and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column headers, projects can be arranged and listed/displayed in ascending or descending alphabetical or numerical order, e.g. for R&D phase, product category or company name. Sample screenshots illustrate the database. Sample screenshots illustrate the database.
Purchase of the subscription provides a 2-Months online access to the data of the R&D Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase and e-mail support will be provided.
Benefits from the R&D Drug Pipeline Database:- New database with no historical burden
- Intuitive use
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
- Antibody
- Cell
- DNA
- Medical Device / Biomaterial
- Peptide
- Protein
- Radiopharmaceutical
- RNA
- Small Molecule
- Vaccine
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
- Anti-Infective Antibodies
- Antibody-Drug Conjugates (ADC)
- Biologic & Immune Therapy of S. aureus Infections
- c-MET/HGF Inhibitors
- CD20 Antibodies
- Coagulation Factors
- CXCR and CXCL Agonists & Antagonists
- Dengue Virus Vaccines
- EGF-R Agonists and Antagonists
- Enzyme Replacement Therapies
- Erythropoiesis Stimulating Agents
- G-CSF and GM-CSF
- HDAC Inhibitors
- HDL Raising Therapies
- Heat shock protein 90 (Hsp90) Inhibitors
- HPV Vaccines
- Human Growth Hormone
- IGF-1R Antagonists
- Insulin
- Interferon
- Interleukin-17 and IL-17R Antagonists
- Janus Kinase (JAK) Inhibitors
- Malaria Vaccines
- NGF Agonists & Antagonists
- Novel Mitotic Kinase Inhibitors
- PDGF-R Agonists and Antagonists
- PI3K-AKT-mTOR Inhibitors
- Ras-Raf-MEK-ERK Inhibitors
- Targeted Therapy of Hepatitis C
- TGF-R Agonists and Antagonists
- TNF Agonists & Antagonists
- Toll-Like Receptor (TLR) Agonists and Antagonists
- VEGF and VEGF-R Agonists and Antagonists
